Department News

1/9/20

Fifteen students in the MD-PhD program at the Jacobs School of Medicine and Biomedical Sciences presented posters at the Tri-Institutional MD-PhD Research Day last fall at the Jacobs School building in downtown Buffalo.

12/18/19

Jerrold C. Winter, PhD, professor of pharmacology and toxicology, is the author of an entertaining and informative new book, “Our Love Affair with Drugs: The History, the Science, the Politics,” published by Oxford University Press.

12/6/19

An abstract co-authored by Rasheen Powell, a doctoral candidate in the Department of Pharmacology and Toxicology, has been selected as a “Neuroscience 2019 Hot Topic” by the Society for Neuroscience.

11/27/19

David Dietz, PhD, associate professor and chair of pharmacology and toxicology, is senior author on a pair of papers dealing with the study of drug relapse.

11/15/19

Sixty-seven oral and poster presentations were showcased at the 13th annual Neuroscience Research Day of the neuroscience program and the Buffalo Chapter of the Society for Neuroscience (SfN).

11/13/19

Two Jacobs School of Medicine and Biomedical Sciences’ researchers studying how to develop novel, non-addicting painkillers have each been issued awards by the Helping to End Addiction Long-term (HEAL) Initiative, a prestigious and highly competitive program from the National Institutes of Health.

10/31/19

The new program, leading to a Bachelor of Science degree, was developed as a collaboration between the Jacobs School of Medicine and Biomedical Sciences and the College of Arts and Sciences.

9/17/19

Eighty-four student-scientists presented projects during the Ninth Annual Buffalo Summer Research Conference, an interdisciplinary forum marking the culmination of their summer research in Buffalo.

8/26/19

An innovative researcher and others who have made significant contributions to their fields and to the Jacobs School of Medicine and Biomedical Sciences were honored with 2019 Faculty-Staff Recognition Awards.

8/20/19

Jun-Xu Li, MD, PhD, has been awarded a five-year, $2 million National Institutes of Health grant to investigate a novel therapy that may prove more powerful than currently available smoking cessation treatments.